(@efimov)

Goal 3: Advance Translational Research

NHLBI Cardiovascular Engineering Strategy

Most impressive and impactful advances in CV diagnostics and therapies came in the last 50 years from CV engineering, including implantable devices and imaging technology. CV engineers are developing next breakthrough technology including tissue engineering and flexible electronics. However, organizational structure of NIH does not have an entity responsible for strategic development of CV engineering. NIBIB does not ...more »

Voting

8 net votes
17 up votes
9 down votes
Active
(@nhlbiforumadministrator1)

Goal 3: Advance Translational Research

Personalized Medicine thru CV bioinformation/tissue repository

There is a need to establish virtual CV biologic tissues and a bioinformational repository for specific CV diseases, including congenital cardiovascular malformations, genetic or other unique cardiomyopathies, such as stress cardiomyopathy and giant cell myocarditis.

Voting

-13 net votes
10 up votes
23 down votes
Active
(@bradley.richmond)

Goal 2: Reduce Human Disease

How can we better understand regional tissue heterogeneity in lung disease?

Many lung diseases (IPF, COPD) are characterized by marked heterogeneity at the tissue level. Unfortunately, most of the tools we currently employ to understand lung disease are unable to elucidate the mechanisms that result in regional heterogeneity. Clinical studies and animal models, while invaluable, generally assume that all lung tissue is similarly affected based on the presence or absence of diagnostic criteria ...more »

Voting

9 net votes
26 up votes
17 down votes
Active